CoChat

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications

Open access
Cabo, Mariona, Offringa, Rienk, Zitvogel, Laurence, Kroemer, Guido, Muntasell, Aura, Galluzzi, Lorenzo · 2017 · OncoImmunology
Cited by 37

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

The goal of cancer immunotherapy is to establish new or boost pre-existing anticancer immune responses that eradicate malignant cells while generating immunological memory to prevent disease relapse. Over the past few years, immunomodulatory monoclonal antibodies (mAbs) that block co-inhibitory receptors on immune effectors cells – such as cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PDCD1, best known as PD-1) – or their ligands – such as CD274 (best known as PD-L1) – have proven very successful in this sense. As a consequence, many of such immune checkpoint blockers (ICBs) have already entered the clinical practice for various oncological indications. Considerable attention is currently being attracted by a second group of immunomodulatory mAbs, which are conceived to activate co-stimulatory receptors on immune effector cells. Here, we discuss the mechanisms of action of these immunostimulatory mAbs and summarize recent progress in their preclinical and clinical development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2017.1371896

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 37

Metadata

Authors
Cabo, M., Offringa, R., Zitvogel, L., Kroemer, G., Muntasell, A., & Galluzzi, L.
Venue
OncoImmunology
Published
2017-08-30
Volume
6
Issue
12
Pages
e1371896
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W4210994832
Cited by
37
References
43
FWCI
2.91
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. https://app.cochat.ai/papers/10.1080/2162402x.2017.1371896
The paper
Cabo, M., Offringa, R., Zitvogel, L., Kroemer, G., Muntasell, A., & Galluzzi, L. (2017). Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology. https://doi.org/10.1080/2162402x.2017.1371896

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.